recycling and remodeling contribute to multiple cellular functions, including cell fusion events during myogenesis. We have identified a tripartite motif (TRIM72) family member protein named MG53 and defined its role in mediating the dynamic process of membrane fusion and exocytosis in striated muscle. MG53 is a muscle specific protein that contains a TRIM motif at the amino terminus and a SPRY motif at the carboxyl terminus. Live cell imaging of GFP-MG53 fusion protein in cultured myoblasts shows that although MG53 contains no transmembrane segment, it is tightly associated with intracellular vesicles and sarcolemmal membrane. RNAi-mediated knockdown of MG53 expression impedes myoblast differentiation, while overexpression of MG53 enhances vesicle trafficking to and budding from sarcolemmal membrane. Co-expression studies indicate that MG53 activity is regulated by a functional interaction with caveolin-3. Our data reveals a new function for TRIM family proteins in regulating membrane trafficking and fusion in striated muscles.
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When myoblasts exit the cell cycle during myogenesis, dramatic changes in membrane organization occur as myoblast fusion allows the formation of multi-nucleated muscle fibers. In addition to cell fusion events, differentiation of myotubes involves establishment of specialized membrane structures (1, 2) . The transverse tubular invagination of sarcolemmal membrane and the intracellular membrane network known as the sarcoplasmic reticulum (SR) are two highly organized membrane architectures in cardiac and skeletal muscle. Establishment of these intricate membrane compartments requires extensive remodeling of the immature myoblast membranes. Dynamic membrane remodeling also contributes to many physiologic processes in mature muscle, including Ca 2+ signaling, trafficking of glucose transporter (GLUT4) and other membrane internalization events involving caveolae structures (3) (4) (5) (6) . Although defects in membrane integrity have been linked to various forms of muscular dystrophy (7, 8) , the molecular machinery regulating these specific membrane recycling and remodeling events in striated muscle is not well defined.
The large tripartite motif (TRIM) family of proteins are involved in numerous cellular functions in a wide variety of cell types. Members of this protein family contain signature motifs that include a RING finger, a zinc binding moiety (BBox), and a coiled-coil structure (RBCC), which invariably comprise the amino-terminal domain of TRIM family members (9) . The carboxyl terminal sequence of TRIM proteins is variable, in some cases a sub-family of TRIM proteins contain a SPRY domain, a sequence first observed in the ryanodine receptor Ca 2+ channel in the SR membrane of excitable cells (10). Extensive studies have revealed that protein-protein interactions in the cytosol mediate the defined functions of TRIM proteins. For example, the ubiquitin-E3 ligase enzymatic activity of several TRIM family members requires the B-box motif (11, 12) . Recent studies have also indicated a role for TRIM proteins in defense against events involving membrane penetration, such as protection against infection by various viruses, including HIV (13) (14) (15) . While most of the studies concentrate on the cytosolic action of TRIM, limited reports have investigated the role of TRIM proteins in membrane signaling or recycling.
We have previously established an immunoproteomic approach that allows definition of novel components involved in myogenesis, Ca 2+ signaling and maintenance of membrane integrity in striated muscle (16) . Using this approach, we have shown that junctophilin is a structural protein that establishes functional communication between SR and transverse-tubule membranes at triad and dyad junctions in striated muscle (17) (18) (19) . Further studies identified mitsugumin 29, a synaptophysinrelated protein that is essential for biogenesis of triad membrane structures and Ca 2+ signaling in skeletal muscle (20, 21) . Screening of this immuno-proteomic library led to the recent identification of MG53, a muscle specific TRIMfamily protein (22) . Domain homology analysis revealed that MG53 contains the prototypical RBCC motifs plus a SPRY domain at the carboxyl-terminus.
Genetic knockout and functional studies reveal that MG53 nucleates the assembly of the sarcolemmal membrane repair machinery to restore cellular integrity following acute damage to the muscle fiber (22) .
Here we present evidence illustrating that MG53, in contrast to other known TRIM proteins, can localize to intracellular vesicles and the sarcolemmal membrane. A functional interaction between MG53 and caveolin-3, another muscle specific protein, plays an essential role in regulating the dynamic process of membrane budding and exocytosis in skeletal muscle.
EXPERIMENTAL PROCEDURES
Plasmids construction -The full-length mouse MG53 cDNA and associated truncation mutants were generated by PCR using the primers described in Supplemental Table 1 . For construction of pCMS-MG53, after digestion by the appropriate restriction enzymes, the PCRamplified cDNA was inserted into pCMS-EGFP vector (Invitrogen) at Nhe I/Xba I sites. For construction of GFP-MG53, GFP-TRIM, GFP-SPRY, MG53-GFP, TRIM-GFP and SPRY-GFP, PCR products were inserted into pEGFP-C1 at the XhoI/XbaI sites, or pEGFP-N1 at the XhoI/KpnI sites. Cell culture -The C2C12 myoblast cell line was purchased from the American Type Culture Collection (Manassas, VA). Cells were grown in a humidified environment at 37°C and 5% CO 2 in DMEM medium for C2C12, or Ham's F12 medium for CHO cells supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 ug/ml streptomycin. In order to induce myotube differentiation, C2C12 myoblasts were grown to confluence and the medium was switched to DMEM containing 2% horse serum, penicillin (100 U/ml), streptomycin (100 μg/ml). For transient transfections, C2C12 myoblasts or CHO cells were plated at 70% confluence in glassbottom dishes. After 24 hours, cells were transfected with plasmids described above using GeneJammer reagent (Stratagene). Cells were visualized by live cell confocal imaging at 24-48 hours after transfection or at times indicated for individual experiments. In some experiments, C2C12 myoblasts were allowed to differentiate into myotubes for the indicated time before observation. Immunostaining and electron microscopyImmunochemical analyses using mAb5259 were carried out as described previously (23) . For MG53 expression in amphibian embryonic cells, cRNA for rabbit MG53 was prepared using a commercial kit (Megascript, Ambion). Newt embryos (1-8 cell stages) were injected with cRNA (~70 ng/embryo), incubated for a day, and analyzed using electron-microscopy as described previously (24) . For tracking the endocytosis using cationic ferritin, a solution containing 10 mg/ml cationic ferritin (cationic ferritin-N, N-dimethyl-1,3-propanediamine, Sigma) and 0.15 M NaCl was injected into the blastocoelic cavity of embryos (~0.6 µl/embryo). Live cell imaging -To monitor intracellular trafficking of GFP-MG53, CHO or C2C12 cells were cultured in glass-bottom dishes (Bioptechs Inc.) and transfected with the plasmids described above. Fluorescence images were captured at 3.18 s/frame using a BioRad2100 Radiance laser scanning confocal microscope with a 63x 1.3NA oil immersion objective. RNAi assay -The target sequence for shRNA knockdown of MG53 is at position 622-642 (GAG CTG TCA AGC CTG AAC TCT) in the mouse by guest on November 15, 2017 http://www.jbc.org/ Downloaded from MG53 cDNA. For caveolin-3, the target sequence is at position 363-380 (GAC ATT CAC TGC AAG GAG ATA). Complementary sense and antisense oligonucleotides were synthesized using sequences described in Supplemental Table 2 . To construct the MG53 shRNA and control plasmids, annealed oligonucleotides were inserted into psiRNA-hH1GFPzeo G2 (InvivoGene) at the Acc 65I/Hind III restriction enzyme sites. For caveolin-3 shRNA and control plasmids, annealed oligonucleotides were inserted into pRNAiDsRed vector (BD Biosciences) at the EcoR I/ BamH I restriction enzyme sites. Each vector has a fluorescent protein expression cassette (green or red) under control of a separate promoter that acts as a marker of cell transfection. All plasmids were confirmed by direct sequencing with flanking primers and the down-regulation of MG53 and caveolin-3 protein expression was examined by western blot analysis. Western blot and co-immunoprecipitation -C2C12 or CHO cells were harvested and lysed with icecold modified RIPA buffer (150 mM NaCl, 5 mM EDTA, 1% NP40, 20 mM Tris-HCl, pH 7.5) in the presence of a cocktail of protease inhibitors (Sigma). 20 μg of total protein were separated on a 4-12% SDS-polyacrylamide gel. Immunoblot of MG53 was performed with either mAb5259 or polyclonal anti-MG53 antibodies. A standard protocol was used for co-immunoprecipitation studies of MG53 and caveolin-3. In brief, skeletal muscle tissue or C2C12 myotubes were lysed in 0.5 ml modified RIPA buffer. The whole cell lysate (500 μg) was incubated overnight with 5 μg polyclonal rabbit anti-MG53, or monoclonal anticaveolin-3 antibody. As a negative control, 500 μg whole cell lysate was incubated with 5 μg normal rabbit or mouse IgG and processed as described above. The immune complexes were collected on protein G-Sepharose beads by incubating for 2 hours and washed four times with RIPA buffer. (Fig. 1B) . Specifically, extensions of the cell surface membranes formed distinct filapodia-like structures in both CHO cells and C2C12 myoblasts that transiently overexpress MG53.
RESULTS

Overexpression
To further examine the MG53-induced changes in cell morphology, we generated two GFP-fusion constructs of MG53, GFP-MG53 and MG53-GFP, with attachment of GFP to the aminoterminus or carboxyl-terminus of MG53, respectively. Although both fusion proteins can be expressed in CHO cells and C2C12 myoblasts (Fig. 1A) , the subcellular distribution and functional effects of GFP-MG53 and MG53-GFP were drastically different. Using confocal microscopy, we found that GFP-MG53 fusion proteins were localized to both intracellular vesicles and cell surface membranes in both CHO and C2C12 cells (Fig. 1C, left panels) . This result is consistent with our electron microscopic localization of MG53 in skeletal muscle fibers (22) , and suggests that MG53 may participate in membrane trafficking events in muscle cells.
Interestingly, the distribution pattern of MG53-GFP fusion protein was mostly cytosolic in both CHO and C2C12 cells (Fig. 1C , right panels), which is in sharp contrast to the membrane-attached distribution of GFP-MG53. In addition, the extensive filapodia-like membrane extensions induced by overexpression of MG53 or GFP-MG53 was completely absent in cells transfected with MG53-GFP. Since shielding the carboxyl-terminus of MG53 by fusion with GFP alters the subcellular distribution of MG53, it is likely that the SPRY motif at the carboxylterminal end of MG53 plays a role in anchoring MG53 to the different membrane compartments (see Fig. 7 ).
Live cell fluorescence imaging identified dynamic trafficking of intracellular vesicles, and active exocytotic fusion and vesicle budding at the cell surface membrane, in cells overexpressing GFP-MG53 (22) . Close examination revealed the occurrence of vesicle fusion events at the surface membrane (Fig. 1D, left panel) . Budding of vesicles containing GFP-MG53 could be clearly identified, as well as released extracellular vesicles observed in the vicinity of transfected cells ( Although there is no membrane-spanning segment or lipid-modification motif in its primary structure, MG53 appears to be primarily restricted to membrane structures in skeletal muscle, based on several observations. First, MG53 was recovered in microsomal membrane vesicles but not in cytosolic fractions during biochemical fractionations of skeletal muscle tissues (not shown). Second, immunohistochemical analysis with mAb5259 showed specific labeling for MG53 in the sarcolemmal and transverse-tubule membranes in longitudinal sections of skeletal muscle fibers ( Fig. 2A) . Moreover, transverse sections revealed localized concentration of MG53 near sarcolemmal membrane, with a broader staining pattern than is typically observed for integral membrane proteins of the sarcolemma (Fig. 2B) . A role for MG53 in intracellular membrane formation was confirmed in amphibian embryonic cells, where injection of MG53 cRNA generated distinct intracellular vesicular structures that can be continuous with the extracellular space. Vesicle formation could be observed by electron microscopy in many cells expressing MG53 (Fig.  2C) . On average, vacuoles near the plasma membrane were frequently found in cells expressing MG53 (42.6 ± 2.3%, data from 21 embryos), which is significantly higher than those of control cells (4.7 ± 1.5% from 11 embryos, p<0.001). These vesicles could make contact with the extracellular space, as illustrated by their ability to uptake ferritin from the extracellular space (Fig. 2D, arrow) .
MG53 contributes to skeletal muscle myogenesis by regulating myoblast differentiation
To directly examine the role of MG53-mediated membrane fusion on the myogenesis of skeletal muscle, we used a specific RNA interference probe to knockdown the expression of endogenous MG53 in differentiated C2C12 myotubes. The efficacy of a small hairpin shRNA probe recognizing the nucleotide sequence 632-652 of the mouse MG53 cDNA in suppressing the expression of MG53 was assayed in CHO cells. For this study, CHO cells were transiently transfected with a 10:1 ratio of plasmids carrying either the shRNA-MG53 cDNA or the MG53 cDNA. As shown in Fig. 3A , a greater than 80% reduction of MG53 expression was observed in cells transfected with shRNA-MG53, as compared with cells transfected with a non-specific shRNA probe.
Acute suppression of MG53 resulted in a marked decrease in C2C12 myotube differentiation (Fig. 3B) . As a control, C2C12 myoblasts transfected with a non-specific shRNA probe exhibited a normal differentiation pattern with numerous multi-nucleated myotubes present by day 5 following serum withdrawal. Mature myotubes were widely distributed by day 10 of differentiation. In contrast, C2C12 myoblasts transfected with the shRNA-MG53 probe formed significantly fewer myotubes at both day 5 and day 10 after serum deprivation-induced differentiation (Fig. 3C) . These results suggest that normal expression of MG53 is necessary for the differentiation of C2C12 myoblasts into myotubes.
Functional interaction between MG53 and caveolin-3 regulates dynamic membrane budding process in skeletal muscle
Our findings suggest that overexpression of MG53 can drive active membrane fusion and budding in both muscle and non-muscle cells, and that down-regulation of MG53 results in compromised capacity of myotube differentiation. As shown in Fig. 4A , MG53 expression is associated with C2C12 myotube differentiation. The expression of MG53 is absent in myoblast stage and is induced following initiation of differentiation. Interestingly, expression of caveolin-3, a muscle-specific caveolin isoform associated with muscle differentiation (25, 26) , follows the initiation of MG53 expression. The specific role of caveolin-3 in muscle differentiation is evidenced by the continuous presence of caveolin-1, a ubiquitous structural protein associated with caveolae in all cell types, throughout all stages of C2C12 differentiation. Using co-immunoprecipitation assay, we found that MG53 can physically interact with caveolin-3 ( Fig. 4B) .
It is interesting to note that the distinct filapodia-like structures appearing in C2C12 myoblast overexpressing MG53 disappeared following differentiation of these myoblasts into myotubes (Fig. 4C, 4E ). Since filapodia-like structures are not observed in either myoblasts that contain no endogenous MG53 or mature muscle fibers that contain endogenous MG53, the action of MG53 may be controlled by repression of MG53 expression in myoblasts and/or by regulatory mechanisms in mature myotubes and adult muscle fibers that may involve accessory proteins. Because caveolin-3 is developmentally regulated and can interact with MG53, we tested whether MG53-induced filapodia-like structure in C2C12 myoblasts or CHO cells could be influenced by the overexpression of caveolin-3.
As shown in Fig. 4D , concurrent overexpression of caveolin-3 and MG53 in either C2C12 myoblasts or CHO cells leads to remarkable inhibition of the appearance of filapodia-like structures associated with GFP-MG53 overexpression. On average, CHO cells or C2C12 myoblasts transfected with caveolin-3 and GFP-MG53 (in a ratio of 10:1) exhibited 74±5% and 82±6% reduction in the appearance of filapodia-like structures, respectively. These results suggest that caveolin-3 represents one of the molecular regulators of MG53-mediated membrane fusion events.
Down-regulation of caveolin-3 inhibits myoblast differentiation into myotubes without affecting filapodia-like structures induced by GFP-MG53 overexpression
To further investigate the role of caveolin-3 in the subcellular distribution of MG53 and the formation of filapodia-like structures, we constructed a caveolin-3 shRNA plasmid that includes an independent red fluorescence protein expression cassette to provide a marker for shRNA transfected cells. Western blot analysis shown in Fig. 5A reveals that the shRNA-cav3 probe can suppress caveolin-3 expression in CHO cells transiently transfected with the caveolin-3 cDNA without affecting the expression of caveolin-1.
While C2C12 myoblasts transfected with a non-specific shRNA exhibit a normal differentiation pattern as shown by the abundant red-fluorescent labeled myotubes in the left panel of Fig. 5B , acute suppression of caveolin-3 could significantly inhibit the differentiation of C2C12 myoblasts into myotubes (Fig. 5B, right panel) . On average, less than 10% of the shRNA-cav3 transfected myoblasts marked by red-fluorescence could differentiate into mature myotubes at day 6 after application of differentiation media (Fig.  5C ). This result is consistent with previous studies by other investigators, who showed that the expression of caveolin-3 is essential for differentiation of C2C12 myotubes (25, 26) .
Confocal microscopic imaging showed that transfection of shRNA-cav3 into C2C12 myoblasts did not appear to affect the subcellular distribution of GFP-MG53 expressed in these cells (Fig. 5D) . In particular, the distinct pattern of vesicular distribution of GFP-MG53 and filapodialike membrane structures remained unaffected by the transient transfection with either shRNA-cav3 or the non-specific shRNA. This result is consistent with the lack of expression of caveolin-3 in the myoblast stage of C2C12 cells.
The efficacy of the shRNA-cav3 probe to knockdown the expression of caveolin-3 in C2C12 myotubes is difficult to assess, due to the intrinsic role of caveolin-3 in mediating myotubes formation (Fig. 5B) . This also complicates analysis of the functional interaction between MG53 and caveolin-3, however additional chemical means can be used to affect caveolin-3 organization in cell membranes.
MG53-mediated exocytosis is enhanced by extraction of cell membrane cholesterol with methyl-β-cyclodextrin
Due to the essential nature of caveolin-3 in myotube differentiation, we tested the effect of methyl-β-cyclodextrin (M-βCD) on C2C12 myoblasts overexpressing GFP-MG53 to further assay the functional impact of MG53-caveolin interaction on membrane recycling. M-βCD can extract cholesterol from cell membranes and has been widely used as an agent to disrupt caveolae structures (27) . As shown in Fig. 6A , myoblasts overexpressing GFP-MG53 exhibited spontaneous fusion of vesicles both intracellularly as well as at sarcolemmal membrane (see Supplemental Movie 1). These spontaneous fusion events are slow and occur in the order of minutes. Following treatment with M-βCD, exocytotic events become greatly enhanced resulting in accelerated membrane fusion and massive budding of membrane vesicles (Fig. 6B) . These initial alterations are rapidly induced, and extended incubation with M-βCD results in solubilization of GFP-MG53 within the myoblast (Fig. 6C) . For visualization of the dynamic changes of membrane fusion events induced by M-βCD treatment, please see the Supplemental Movie 2. These results re-enforce our observation that caveolin-mediated internalization of membrane vesicles likely play a regulatory role in preventing excessive exocytosis generated by MG53 overexpression.
TRIM and SPRY domains of MG53 contribute differentially to membrane targeting and trafficking
Our observation shown in Fig. 1C revealed a remarkable polarity of GFP fusion to MG53 in the intracellular distribution of MG53. In particular, fusion of GFP to the carboxyl-terminal end of MG53 alters the ability of MG53 to partition to the vesicular compartment and to target to sarcolemmal membrane. To further test the function of the TRIM and SPRY domains in facilitating the membrane-fusion function of MG53, we generated a series of deletion mutants coupled to GFP (Fig. 7A) .
To analyze the subcellular localization of these mutant constructs of MG53, confocal microscopic imaging was applied to C2C12 myoblasts following transient expression. As shown in Fig. 7B (right panels) , GFP-TRIM or TRIM-GFP were predominantly localized to intracellular vesicles without apparent labeling of sarcolemmal membrane. This result suggests that the SPRY domain, which is absent from GFP-TRIM or TRIM-GFP, is necessary for targeting of MG53 to sarcolemmal membrane. The fact that MG53-GFP exhibited a predominantly cytosolic distribution (Fig. 7B, left panel) , further supports the role of SPRY in targeting MG53 to the cell surface membrane.
Interestingly, although GFP-SPRY or SPRY-GFP displayed a predominantly cytosolic pattern of distribution, they are clearly excluded from intracellular vesicles (Fig. 7B, middle panels) . The cytosolic distribution pattern coupled with the exclusion of localization at intracellular vesicles of GFP-SPRY and SPRY-GFP likely reflects the role of TRIM. Presumably, the TRIM motif can mediate the adherence of MG53 to intracellular vesicles (Fig. 7B, right panels) . The SPRY domain is insufficient to target to the sarcolemma by itself, therefore the TRIM domain must be present in tandem with the SPRY domain for proper trafficking of MG53 to sarcolemmal membrane.
In addition, our coimmunoprecipitation data shows that caveolin-3 interacts with the TRIM motif of MG53 (Fig. 7C) . Thus, it is possible that the functional interaction between MG53 and caveolin-3 may underlie some of the cellular factors contributing to the diffuse pattern of GFP-SPRY and SPRY-GFP in C2C12 myoblasts.
Overall, the regulated distribution of MG53 to the cell surface and intracellular compartments would likely result from coordinated action between the TRIM and SPRY domains. This requirement for both TRIM and SPRY for proper MG53 subcellular localization also has apparent functional significance, as none of these deletion mutants display the filapodia-like structures or the robust vesicle budding events observed from overexpression of full-length MG53. thought to be terminally differentiated, extensive remodeling of sarcolemmal membrane still takes place under physiological and pathophysiological conditions, including trafficking and internalization of membrane transporters and muscle fiber regeneration following injury or denervation (28, 29) . The molecular machinery that regulates this process during development, disease and senescence are not well understood. Here we show that a novel TRIM/RBCC family member protein, MG53, is a key component in driving membrane fusion, budding and exocytosis. MG53 is unique in that it is only observed in striated muscle cells and, in contrast to most other defined TRIM/RBCC members, it is intimately associated with membrane trafficking.
The TRIM family of proteins is large and displays diverse cell biological functions (12, 30) . Previous studies have linked TRIM protein function to several human diseases, including muscular dystrophy, viral infection and cancer progression (9) . Attempts at understanding the cell biological function of TRIM proteins have focused on the role of various protein motifs in mediating intracellular signaling events. For example, the coiled-coiled motif has been shown to facilitate protein dimerization, a characteristic required for coordinated function of TRIM proteins (31, 32) . The RING and B-box motifs contain intrinsic E3-ligase enzymatic activity, which has been shown to regulate protein degradation in many cell types (33) , particularly in the progression of muscle atrophy (12) . Previous studies have also linked TRIM proteins to neuronal outgrowth and structural plasticity (34) , as well as synaptic vesicle exocytosis (35) . Since a limited number of the TRIM family members contain a carboxylterminal SPRY domain, the function of the SPRY domain has only recently been examined (14, (36) (37) (38) . Several studies have suggested that a variable region within the SPRY domain of TRIM5α in rhesus monkeys can mediate immunity to HIV infection (13) (14) (15) 37) . The MG53 gene identified in our study belongs to this TRIM sub-family containing a SPRY domain. Our studies with MG53 reveal a new cell biological function for the TRIM protein family in striated muscle, which involves membrane remodeling and signaling that is dependent on the presence of a SPRY domain in tandem with the TRIM motif.
Our previous studies showed that MG53 can function in the repair of sarcolemmal membrane following acute cell injury (22) . Those finding are consistent with our observation here that MG53 participates in vesicle trafficking in the course of normal cellular physiology. It has been previously suggested that the cell membrane repair process is an emergency response by the cell, where cellular components with a certain role in the course of normal cell function are repurposed to act in the resealing of damaged cell membranes (39) . Considering that translocation of intracellular vesicles to injury sites on the cell membrane would be an essential step in repair of the membrane, a role for MG53 in the normal process of intracellular vesicle trafficking seems to be in agreement with another critical function in repairing potentially catastrophic injury to muscle cells.
Based on our electron and confocal microscopic results, we found MG53 is tethered to intracelluar vesicles that traffic between different subcellular compartments, with the majority of the protein restricted to a space near sarcolemmal membrane. MG53 can drive the active exocytoic process in both excitable and non-excitable cells, as evidenced by the appearance of filapodia-like structures in cells overexpressing either MG53 or GFP-MG53. In skeletal muscle, MG53 appears to contribute to myogenesis, as RNAi mediated suppression of MG53 attenuates myoblast fusion and myotube formation. These findings should provide new insights into our understanding of TRIM protein function.
The primary amino acid sequence of MG53 contains no transmembrane domains or lipidmodification motifs, suggesting the localization of MG53 may involve interaction with accessory proteins. Through biochemical studies we found that MG53 can interact with caveolin-3, a muscle specific protein associated with caveolae. Expression of MG53 precedes the appearance of caveolin-3 during myogenic differentiation of C2C12 cells. Thus, caveolin-3 may represent a regulatory factor that moderates the robust membrane trafficking events generated by the presence of MG53. We show that overexpression of caveolin-3 can downregulate membrane budding induced by MG53 overexpression and prevent the formation of filapodia-like structures.
For maintenance of muscle membrane integrity, a balance of exocytosis and membrane internalization must be well controlled under physiologic conditions. The identified MG53-caveolin interaction has important implications for muscle physiology and pathophysiology. Extensive studies have linked caveolin-3 to muscle differentiation (40). Limb-girdle muscular dystrophy (LGMD) is associated with a mutation in caveolin-3 that leads to loss of approximately 95% of caveolin-3 expression. A caveolin-3 null mutation in mice produces defects in skeletal muscle membrane trafficking and a concurrent disruption of transverse-tubule membrane organization (40-42), phenotypes that are associated with LGMD. Interestingly, transgenic overexpression of caveolin-3 has also been shown to result in severe muscular degeneration similar to Duchenne muscular dystrophy (43). Therefore, caveolin-3 function appears to be essential for myogenesis and maintenance of muscle integrity. Our results suggest that caveolin-3 expression can control MG53 activity. Presumably, some aspects of caveolin-3 function may involve its interaction with MG53, so the loss of caveolin-3 in development may lead to aberrant MG53-mediated membrane remodeling. One can envision that targeting MG53-caveolin3 interaction would represent an effective therapy for muscle related disease involving altered membrane structures.
Trafficking of intracellular vesicles containing MG53 to sarcolemmal membrane requires coordinated function of the TRIM and SPRY domains. Our studies show that the SPRY domain is essential for targeting of MG53 to the cell membrane, while the TRIM domain mediates interaction with intracellular vesicles in the context of the MG53 molecule. These results not only demonstrate the importance of a coordinated action of TRIM and SPRY to facilitate membrane trafficking properties of MG53, they also suggest the possibility that other TRIM family proteins carrying a similar SPRY domain may also exhibit membrane modifying properties. Indeed, a previous study by Perez-Caballero, et al. demonstrated that both TRIM and SPRY domains of TRIM5α are required to provide cellular resistance to retroviral infection (44), although the membrane trafficking properties of TRIM5α have yet to be examined. It remains to be determined if TRIM-SPRY intermolecular interactions produce intrinsic membrane targeting ability or if additional cellular factors beyond caveolin-3 are required.
In conclusion, we have shown that MG53 is an active component of membrane fusion, exocytosis and vesicle budding that play an important role in myogenesis of striated muscle cells. The presence of TRIM and SPRY motif in MG53 and a functional interaction with caveolin-3 is essential in regulating membrane trafficking and cellular signaling events across sarcolemmal membrane. Figure 7
GFP-TRIM
